| 摘要 |
The present invention relates to the use of a nucleic acid construct comprising
(a) a cis regulatory element including a polynucleotide having the sequence set forth in SEQ ID NO:8 and at least one copy of the sequence as set forth in SEQ ID NO: 6;
(b) an endothelial cell promoter; and
(c) a polynucleotide sequence encoding a cytotoxic polypeptide comprising the extracellular region of TNFR1 and the trans-membrane and intracellular regions of Fas cytotoxic polypeptide;
for the manufacture of a medicament for inhibiting angiogenesis in a subject in need thereof;
wherein said subject is being treated concomitantly with at least one additional chemotherapeutic and/or radiotherapeutic modality, said additional therapeutic modality selected capable of further potentiating said inhibition of angiogenesis in a synergic manner. |
